GSK snags $38.5 million BARDA contract to pursue Gram-negative antibiotic
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline won a two-year $38.5 million contract on 6 September from the US Biomedical Advanced Research and Development Authority (BARDA) to develop the firm's investigational antibiotic GSK2251052 against Gram-negative infections. The contract has the potential to be extended two additional years for a total of $94.5 million.